DYAI DYADIC INTERNATIONAL INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1213809 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-7.6%
TTM net income YoY4.7%
TTM EPS YoY13.0%
Revenue 3-yr CAGR1.5%
Net income 3-yr CAGR—
Margins
Gross margin17.9%
Operating margin-236.7%
Net margin-226.9%
FCF margin—
EBITDA margin—
Returns
ROE-47,256.0%
ROA-71.4%
ROIC (approx.)—
Asset turnover0.31x
Leverage & solvency
Liabilities / assets132.5%
Debt / equity—
Current ratio1.69x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.00x
Accruals ratio0.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $3.09M | $3.50M | $2.90M | $2.93M | $2.40M |
| Cost of revenue | $2.32M | $1.19M | $1.98M | $2.12M | $1.94M |
| Gross profit | $770,485 | $2.30M | $922,957 | $807,110 | $459,393 |
| R&D expense | $2.15M | $2.04M | $3.30M | $4.50M | $8.39M |
| SG&A expense | $5.76M | $6.13M | $5.82M | $6.42M | $6.70M |
| Operating income | -$7.19M | -$5.90M | -$8.23M | -$10.17M | -$14.73M |
| Pretax income | -$7.33M | -$5.76M | -$6.77M | -$9.83M | -$13.12M |
| Income tax | — | — | — | — | $0 |
| Net income | -$7.36M | -$5.81M | -$6.80M | -$9.74M | -$13.07M |
| EPS (basic) | -0.23 | -0.20 | -0.24 | -0.34 | -0.47 |
| EPS (diluted) | -0.23 | -0.20 | — | — | -0.47 |
| Weighted avg. shares (diluted) | 32.62M | 29.32M | — | — | 27.84M |
| Balance sheet | |||||
| Cash & equivalents | $4.62M | $6.51M | $6.52M | $5.79M | $15.75M |
| Short-term investments | $2.70M | $2.76M | — | — | — |
| Receivables | $1.09M | $237,027 | $466,159 | $330,001 | $277,831 |
| Current assets | $9.90M | $9.83M | $8.07M | $13.42M | $21.01M |
| Total assets | $9.95M | $9.93M | $8.22M | $13.71M | $21.30M |
| Current liabilities | $3.69M | $2.45M | $2.25M | $2.45M | $2.56M |
| Total liabilities | $8.71M | $7.46M | $2.34M | $2.63M | $2.91M |
| Shareholders' equity | $1.23M | $2.47M | $5.88M | $11.09M | $18.39M |
| Shares outstanding | 36.19M | 29.84M | 28.81M | 28.56M | 28.23M |
| Cash flow statement | |||||
| Operating cash flow | -$5.70M | -$3.97M | -$6.73M | -$8.08M | -$11.28M |
| Investing cash flow | $82,085 | -$1.88M | $7.45M | -$2.37M | $5.22M |
| Financing cash flow | $4.96M | $5.85M | $0 | $543,591 | $1.23M |
| Stock-based compensation | $930,183 | $1.13M | $1.24M | $1.89M | $1.78M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.